Free
Clinical Science  |   September 1998
The Effect of Adding a Minidose of Clonidine to Intrathecal Sufentanil for Labor Analgesia
Author Notes
  • (Mercier, Dounas, Bouaziz) Staff Anesthesiologist, Departement d'Anesthesie-Reanimation, Hopital Antoine Beclere.
  • (Des Mesnards-Smaja, Foiret, Vestermann) Staff Anesthesiologist, Service d'Anesthesie, CMC Foch.
  • (Fischler) Professor of Anesthesiology, Service d'Anesthesie, CMC Foch.
  • (Benhamou) Professor of Anesthesiology, Departement d'Anesthesie-Reanimation, Hopital Antoine Beclere.
  • Received from the Departement d'Anesthesie-Reanimation, Hopital Antoine Beclere, Clamart, and the Service d'Anesthesie, CMC Foch, Suresnes, France. Submitted for publication October 8, 1997. Accepted for publication April 24, 1998. Presented in part at the annual meeting of the American Society of Anesthesiologists, San Diego, California, October 21, 1997.
  • Address correspondence to Dr. Benhamou: Departement d'Anesthesie-Reanimation, Hopital Antoine Beclere, 157 rue de la Porte de Trivaux, 92141 Clamart CEDEX, France. Address electronic mail to: dBenhamou.beclere@invivo.edu
  • Reprints will not be available from the authors.
Article Information
Clinical Science
Clinical Science   |   September 1998
The Effect of Adding a Minidose of Clonidine to Intrathecal Sufentanil for Labor Analgesia
Anesthesiology 9 1998, Vol.89, 594-601.. doi:
Anesthesiology 9 1998, Vol.89, 594-601.. doi:
Key words: [Greek small letter alpha]2-Adrenergicagonists; combined spinal epidural anesthesia; obstetrics; pain relief; regional anesthesia.
INTRATHECAL sufentanil (5 - 10 [micro sign]g) has been shown to reduce pain without producing motor blockade during the latent phase of the first stage of labor. [1-5] The combination of intrathecal sufentanil with other drugs has been investigated primarily in an attempt to prolong this relatively short-lasting labor analgesia (90 - 120 min mean duration). The addition of 250 [micro sign]g intrathecal morphine or 200 [micro sign]g intrathecal epinephrine has been disappointing; the former slightly prolonged the duration of action of 10 [micro sign]g intrathecal sufentanil at the expense of a high incidence of side effects, [2] and the latter had little [2] or no effect at all. [4] In contrast, it has been shown that the addition of 2.5 mg intrathecal bupivacaine significantly prolongs the duration of 10 [micro sign]g intrathecal sufentanil. [6] However, the addition of 2.5 mg intrathecal bupivacaine sometimes produces motor blockade [7-9] and hypotension that can be severe. [10] When 200 [micro sign]g intrathecal epinephrine is added to this combination, the duration of analgesia is further prolonged, but motor blockade appears less rare. [11] 
The [Greek small letter alpha]2-adrenergicagonist clonidine produces analgesia by a primarily spinal mechanism when administered intrathecally and potentiates intrathecal - epidural opioids but does not produce motor blockade. [12] In preliminary results published by Chiari et al.,[double vertical bar]# the addition of 100 - 200 [micro sign]g clonidine prolonged the duration of action of intrathecal sufentanil during labor. However, the incidence of hypotension increased when these doses of clonidine were used. The combination of 30 [micro sign]g clonidine and 5 [micro sign]g sufentanil was assessed recently in a small, open-label, nonrandomized study conducted at our institution. [13] This dose of clonidine also significantly increased the duration of action of intrathecal sufentanil during labor and the incidence of hypotension was not increased. However, it was impossible to draw any definite conclusions because of the study design. Thus we designed a prospective, randomized, double-blinded study to assess the effect of adding 30 [micro sign]g clonidine to 5 [micro sign]g intrathecal sufentanil during labor.
Materials and Methods
After we received institutional review board approval at both centers and written informed patient consent, we enrolled 53 parturients who requested epidural analgesia. Inclusion criteria included age >or= to 18 yr, weight <or= to 100 kg, height between 150 and 190 cm, American Society of Anesthesiologists physical status 1 or 2, nulliparity, uncomplicated full-term pregnancy, singleton pregnancy in vertex presentation, regular and painful uterine contractions, cervical dilation between 2 and 5 cm, normal fetal heart rate tracings, and initial systolic blood pressure (SBP) >or= to 115 mmHg.
After a preload of 250 - 500 ml lactated Ringer's solution, a "neddle through needle" combined spinal epidural technique was performed with the parturient in the sitting position. A 8-cm (overall, 10.5 cm) 18-gauge Tuohy needle (Portex, Hythe, UK) was inserted into the epidural space at either the L2-L3 or the L3-L4 interspace using a loss-of-resistance-to-saline technique. A 12-cm, 27-gauge Whitacre spinal needle (Vigon, Ecouen, France) was passed through the epidural needle into the subarachnoid space. After a clear, free flow of cerebrospinal fluid was obtained, the study solution was injected through the spinal needle. The spinal needle was removed, and a 20-gauge epidural catheter (Portex) was inserted 3 - 5 cm into the epidural space. Aspiration was immediately attempted, if no fluid was obtained, a test dose of 5 mg bupivacaine (without epinephrine) was injected to check for intrathecal misplacement of the catheter. [14] Patients were then placed in the recumbent position with left uterine displacement and head elevation.
Patients received intrathecally either 5 [micro sign]g sufentanil plus 30 [micro sign]g clonidine (SUF-CLO) or 5 [micro sign]g sufentanil alone (SUF) in a total volume of 2 ml preservative-free saline. Both the patient and the investigator were blinded to the study solution, which was prepared by an anesthesiologist not involved in the patients' care, according to the group indicated in numbered sealed opaque envelopes. These envelopes had been prepared using a block-of-four random Table withstratification to allocate the same number of patients in the two groups within each center.
The primary outcome variable was the duration of spinal analgesia defined as the time elapsed from intrathecal injection to the patient's first request for additional analgesia. Pain was assessed using a visual analog pain score (VAPS) (0 = no pain, 100 = worst imaginable pain) immediately before study drug injection; 5, 10, 15, 20, 30 min after injection; and every 15 min thereafter. On patient request, additional analgesia was provided via the epidural catheter using 12 ml 0.125% bupivacaine.
The upper level of sensory changes was determined in the mid-clavicular line using an alcohol swab. Blood pressure and heart rate were measured using an automated device (Dinamap; Critikon, Tampa, FL) every 5 min throughout the period of intrathecal analgesia, and additional measurements were made if abnormal fetal or maternal symptoms or signs were observed. For each parturient, the minimal SBP observed during the entire period of spinal analgesia (i.e., before any supplemental analgesia via the epidural catheter) was noted specifically. Hypotension defined as an SBP <95 mmHg or a decrease >25% in SBP was documented and systematically treated by an intravenous injection of ephedrine (3 - 9 mg) that was repeated as needed. Motor blockade was assessed using the Bromage's scale modified by Phillips. [15] Oxyhemoglobin saturation was monitored continuously by pulse oximetry (Nellcor 200, Hayward, CA). Sedation, pruritus, and nausea were rated subjectively as none, mild, moderate, or severe. All of these parameters were recorded at the same intervals as VAPS, except sensory changes and motor blockade, which were recorded 10, 20, and 30 min after intrathecal injection and every 15 min thereafter until the end of intrathecal analgesia.
Fetal heart rate and uterine activity were monitored throughout labor using external cardiotocodynamometry. During the period of intrathecal analgesia, any fetal heart rate abnormality was recorded by the anesthesiologist in accordance with the obstetric team (both blinded to the study drug). The following classification was used: absent or decreased variability, early decelerations, late decelerations, variable decelerations, and bradycardia. The duration of the first and second stages of labor, mode of delivery, total intravenous ephedrine and local anesthetic requirements (excluding supplemental dosing for instrumental or cesarean delivery), and neonatal Apgar scores with arterial umbilical pH were also recorded.
Data are expressed as mean +/- SD unless stated otherwise. Groups were compared for single parametric, ordinal, and nominal variables by Student's unpaired t test, the Mann-Whitney U test, and Fisher's exact test or chi-squared analysis, respectively. The duration of analgesia was determined by Kaplan-Meier survival analysis followed by the log-rank test. The VAPS and hemodynamic data are presented using 95% confidence intervals [16] and were compared using analysis of variance for repeated measures, followed by Student's unpaired t tests with Bonferroni corrections to assess differences between groups at each time point. [17] Upper levels of sensory changes are presented as medians with the interquartile range in box plots and were compared using Mann-Whitney U tests with Bonferroni corrections to assess differences between groups at each time point. P < 0.05 was considered significant.
Results
Fifty-three patients were enrolled in the study. No technical difficulty was encountered during the combined spinal epidural procedure, and cerebrospinal fluid was identified in all patients. However, one patient had no analgesia at all within 15 min of the injection (SUF-CLO group). Another patient had an emergency cesarean delivery (SUF-CLO group) 35 min after the intrathecal injection. A third patient (SUF-CLO group) had rapid cervical dilatation and an instrument-assisted vaginal delivery 110 min after the intrathecal injection without requesting additional analgesia. These three patients were excluded, so data from 50 patients were available. Patient characteristics, gestational age, baseline cervical dilation, rate of spontaneous or augmented or induced labor, weight of the neonate (Table 1), and baseline VAPS (Table 2) were comparable for the two groups.
Table 1. Demographic and Obstetric Data
Image not available
Table 1. Demographic and Obstetric Data
×
Table 2. Labor Analgesia Data and Maternal Side Effects during Intrathecal Analgesia
Image not available
Table 2. Labor Analgesia Data and Maternal Side Effects during Intrathecal Analgesia
×
(Figure 1) illustrates the duration of intrathecal analgesia as the percentage of patients not requesting additional analgesia versus time after the intrathecal injection. The duration of analgesia was longer in the SUF-CLO group than in the SUF group: 125 +/- 46 min versus 97 +/- 30 min (P = 0.007, Table 2).
Figure 1. The duration of spinal analgesia, as the percentage of parturients not requesting additional analgesia, after intrathecal injection of 5 [micro sign]g sufentanil plus 30 [micro sign]g clonidine (dotted line) or 5 [micro sign]g sufentanil alone (solid line). The two groups differ according to Kaplan-Meier survival analysis followed by the log-rank test.
Figure 1. The duration of spinal analgesia, as the percentage of parturients not requesting additional analgesia, after intrathecal injection of 5 [micro sign]g sufentanil plus 30 [micro sign]g clonidine (dotted line) or 5 [micro sign]g sufentanil alone (solid line). The two groups differ according to Kaplan-Meier survival analysis followed by the log-rank test.
Figure 1. The duration of spinal analgesia, as the percentage of parturients not requesting additional analgesia, after intrathecal injection of 5 [micro sign]g sufentanil plus 30 [micro sign]g clonidine (dotted line) or 5 [micro sign]g sufentanil alone (solid line). The two groups differ according to Kaplan-Meier survival analysis followed by the log-rank test.
×
(Figure 2) illustrates the onset of intrathecal analgesia during the first 45 min. The VAPS decreased dramatically and significantly in both groups after intrathecal injection, and no statistical differences were detected between the groups. All parturients had effective analgesia (VAPS <or= to 25 mm) at 15 min.
Figure 2. The onset of spinal analgesia assessed by visual analog pain score (VAPS), after intrathecal injection of 5 [micro sign]g sufentanil plus 30 [micro sign]g clonidine (SUF-CLO) or 5 [micro sign]g sufentanil alone (SUF). Each point represents the mean +/- 95% confidence interval. All VAPSs beyond baseline differ from their respective baseline values, but there was no significant difference between the two groups.
Figure 2. The onset of spinal analgesia assessed by visual analog pain score (VAPS), after intrathecal injection of 5 [micro sign]g sufentanil plus 30 [micro sign]g clonidine (SUF-CLO) or 5 [micro sign]g sufentanil alone (SUF). Each point represents the mean +/- 95% confidence interval. All VAPSs beyond baseline differ from their respective baseline values, but there was no significant difference between the two groups.
Figure 2. The onset of spinal analgesia assessed by visual analog pain score (VAPS), after intrathecal injection of 5 [micro sign]g sufentanil plus 30 [micro sign]g clonidine (SUF-CLO) or 5 [micro sign]g sufentanil alone (SUF). Each point represents the mean +/- 95% confidence interval. All VAPSs beyond baseline differ from their respective baseline values, but there was no significant difference between the two groups.
×
The spread of the upper level of sensory changes during intrathecal analgesia and at the time of epidural injection is shown in Figure 3A (SUF-CLO group) and Figure 3B (SUF group). There were no significant differences between the groups. No patient in any group had sensory changes above T2.
Figure 3. Box plots representing the spread of the upper level of sensory changes to cold in parturients receiving intrathecal injections of (A) 5 [micro sign]g sufentanil plus 30 [micro sign]g clonidine (SUF-CLO) or (B) 5 [micro sign]g sufentanil alone (SUF). The horizontal line within the box represents the median, whereas the box itself represents the interquartile range, with outliers represented by open circles. There was no significant difference between groups, and cephalad sensory changes never exceeded T2.
Figure 3. Box plots representing the spread of the upper level of sensory changes to cold in parturients receiving intrathecal injections of (A) 5 [micro sign]g sufentanil plus 30 [micro sign]g clonidine (SUF-CLO) or (B) 5 [micro sign]g sufentanil alone (SUF). The horizontal line within the box represents the median, whereas the box itself represents the interquartile range, with outliers represented by open circles. There was no significant difference between groups, and cephalad sensory changes never exceeded T2.
Figure 3. Box plots representing the spread of the upper level of sensory changes to cold in parturients receiving intrathecal injections of (A) 5 [micro sign]g sufentanil plus 30 [micro sign]g clonidine (SUF-CLO) or (B) 5 [micro sign]g sufentanil alone (SUF). The horizontal line within the box represents the median, whereas the box itself represents the interquartile range, with outliers represented by open circles. There was no significant difference between groups, and cephalad sensory changes never exceeded T2.
×
The incidence of hypotension during intrathecal analgesia was increased five times (63%) in the SUF-CLO group when compared with the SUF group (12%; P = 0.0003), and the minimal SBP observed was significantly lower in the SUF-CLO group (Table 2). Ephedrine requirements (median +/- interquartile [range]) were also greater: 7.5 +/- 16.5 [0 - 25.5] versus 0 +/- 0 [0 - 6] mg (P < 0.0001). Despite prompt treatment of hypotension with intravenous ephedrine, the SBP remained significantly lower in the SUF-CLO group (P = 0.02; Figure 4A). In addition, administration of ephedrine was still required 65 - 120 min after intrathecal injection on four occasions in the SUF-CLO group, whereas no patient had hypotension beyond 45 min in the SUF group (Figure 4B). The incidence of abnormal fetal heart rate patterns during the first 30 min after intrathecal injection, Apgar scores, and umbilical arterial pH were similar in both groups (Table 3). Hypotension during the 30-min period after redosing with 12 ml 0.125% bupivacaine in the epidural catheter was less pronounced (SUF-CLO vs. SUF group: 5 cases vs. 2 cases, and 0 +/- 0.75 [0 - 15] vs. 0 +/- 0 [0 - 6] mg for ephedrine requirements; difference not significant).
Table 3. Fetal Heart Rate Patterns during the First 30 min after Intrathecal Injection and Neonatal Outcome Data
Image not available
Table 3. Fetal Heart Rate Patterns during the First 30 min after Intrathecal Injection and Neonatal Outcome Data
×
Figure 4. (A) Systolic blood pressure (SBP) after intrathecal injection of 5 [micro sign]g sufentanil plus 30 [micro sign]g clonidine (SUF-CLO) or 5 [micro sign]g sufentanil alone (SUF). Despite prompt treatment of hypotension with intravenous ephedrine, the SBP remained significantly lower in the SUF-CLO group (P = 0.02). *P < 0.05 with Bonferroni corrections compared with the SUF group. (B) Kaplan-Meier survival analysis representing the time course of intravenous ephedrine administration after intrathecal injection of 5 [micro sign]g sufentanil plus 30 [micro sign]g clonidine (dotted line) or 5 [micro sign]g sufentanil alone (solid line). Administration of ephedrine was still required 65 - 120 min after intrathecal injection on four occasions in the SUF-CLO group, whereas no patient had hypotension beyond 45 min in the SUF group.
Figure 4. (A) Systolic blood pressure (SBP) after intrathecal injection of 5 [micro sign]g sufentanil plus 30 [micro sign]g clonidine (SUF-CLO) or 5 [micro sign]g sufentanil alone (SUF). Despite prompt treatment of hypotension with intravenous ephedrine, the SBP remained significantly lower in the SUF-CLO group (P = 0.02). *P < 0.05 with Bonferroni corrections compared with the SUF group. (B) Kaplan-Meier survival analysis representing the time course of intravenous ephedrine administration after intrathecal injection of 5 [micro sign]g sufentanil plus 30 [micro sign]g clonidine (dotted line) or 5 [micro sign]g sufentanil alone (solid line). Administration of ephedrine was still required 65 - 120 min after intrathecal injection on four occasions in the SUF-CLO group, whereas no patient had hypotension beyond 45 min in the SUF group.
Figure 4. (A) Systolic blood pressure (SBP) after intrathecal injection of 5 [micro sign]g sufentanil plus 30 [micro sign]g clonidine (SUF-CLO) or 5 [micro sign]g sufentanil alone (SUF). Despite prompt treatment of hypotension with intravenous ephedrine, the SBP remained significantly lower in the SUF-CLO group (P = 0.02). *P < 0.05 with Bonferroni corrections compared with the SUF group. (B) Kaplan-Meier survival analysis representing the time course of intravenous ephedrine administration after intrathecal injection of 5 [micro sign]g sufentanil plus 30 [micro sign]g clonidine (dotted line) or 5 [micro sign]g sufentanil alone (solid line). Administration of ephedrine was still required 65 - 120 min after intrathecal injection on four occasions in the SUF-CLO group, whereas no patient had hypotension beyond 45 min in the SUF group.
×
Maternal heart rates during intrathecal analgesia were significantly higher in the SUF-CLO group (P < 0.0001; Figure 5); more precisely, it did not decrease in this group when compared with baseline values (P = 0.19 by one-way analysis of variance for repeated measures), whereas it did in the SUF group (P < 0.0001).
Figure 5. The maternal heart rate (MHR) after intrathecal injection 5 [micro sign]g sufentanil plus 30 [micro sign]g clonidine (SUF-CLO) or 5 [micro sign]g sufentanil alone (SUF). The MHR was significantly higher in the SUF-CLO group (P < 0.0001). *P < 0.05 with Bonferroni corrections compared with the SUF group.
Figure 5. The maternal heart rate (MHR) after intrathecal injection 5 [micro sign]g sufentanil plus 30 [micro sign]g clonidine (SUF-CLO) or 5 [micro sign]g sufentanil alone (SUF). The MHR was significantly higher in the SUF-CLO group (P < 0.0001). *P < 0.05 with Bonferroni corrections compared with the SUF group.
Figure 5. The maternal heart rate (MHR) after intrathecal injection 5 [micro sign]g sufentanil plus 30 [micro sign]g clonidine (SUF-CLO) or 5 [micro sign]g sufentanil alone (SUF). The MHR was significantly higher in the SUF-CLO group (P < 0.0001). *P < 0.05 with Bonferroni corrections compared with the SUF group.
×
No parturient had any motor blockade. Oxyhemoglobin saturation never decreased to <93% while parturients were breathing ambient air. There were no other significant differences in maternal side effects during intrathecal analgesia, although the incidence of mild sedation was twice as high in the SUF-CLO group (46 vs. 23%; P = 0.14; Table 2).
The progress of labor (cervical dilation at reinjection, intrathecal injection to delivery, stage 1 and stage 2 duration) and the mode of delivery were not significantly different between the two groups (Table 1). The total dose of bupivacaine administered epidurally during labor after the period of intrathecal analgesia was similar in both groups (Table 2).
Discussion
Little information is available in the literature regarding the use of intrathecal clonidine for labor pain relief, [12] yet reports have been published in abstracted form [18], [double vertical bar]# or as a preliminary report. [13] This prospective, randomized, double-blinded study shows that the addition of 30 [micro sign]g clonidine to 5 [micro sign]g intrathecal sufentanil extends the duration of labor analgesia but also increases the incidence of hypotension.
Analgesia and Choice of Doses
The dose of intrathecal sufentanil used most often during labor is 10 [micro sign]g. However, this dose may depress the ventilatory response to carbon dioxide in the parturient.** In addition, 10 [micro sign]g sufentanil has a significantly greater effect than 5 [micro sign]g on maternal end-tidal carbon dioxide level. [19] Furthermore, there are several cases of transient difficulties in breathing and/or an inability to swallow using 10 [micro sign]g, [3,20] and at least three cases of respiratory depression [21] or even arrest [22,23] after a single intrathecal injection of sufentanil with doses ranging from 10 - 15 [micro sign]g. Cervical [5] or even facial sensory changes [20] have also been reported with this dosage. On the other hand, cephalad sensory changes never exceeded T2 in the current study when only 5 [micro sign]g intrathecal sufentanil was administered (Figure 3B). This is in accordance with recent results of Gautier et al. [24] In addition, 5 [micro sign]g intrathecal sufentanil [1] or even less has been reported to provide adequate analgesia during early labor.[dagger, dagger] [double dagger] [double dagger] This was confirmed in the current study (Figure 2). Finally, the mean duration of analgesia ranged from 90 - 123 min with 10 [micro sign]g intrathecal sufentanil, [2-6,25] 90 - 104 min with 7 - 5 [micro sign]g, [1,13],# and still 97 min with 5 [micro sign]g in the current study. The similar duration of analgesia using either 5 or 10 [micro sign]g was confirmed in two randomized preliminary studies,[dagger, dagger] [section] [section] although another randomized study suggests that a dose - response relationship might exist. [26] 
Of note, a 5-mg bupivacaine test dose was administered epidurally in the current study soon after the intrathecal injection, for safety considerations described in another publication. [14] This epidural test dose did not seem to prolong the duration of spinal analgesia when compared with durations reported using a similar dose of intrathecal sufentanil without a concurrent test dose. [1,13] [section] [section] Although this was not a bias because it was used in both groups, this epidural test dose may have interacted with intrathecal sufentanil (+/- clonidine) to strengthen the intensity of analgesia,[double dagger] [double dagger] and thus may have increased hemodynamic effects (see below).
We chose to investigate a low dose (30 [micro sign]g) of intrathecal clonidine based on the following considerations. First, clonidine has higher efficacy after intrathecal rather than after epidural or systemic administration [12] and acts synergistically with opioids. [27,28] Second, a study performed in rats suggests that low-dose systemic clonidine enhances pregnancy-induced analgesia to visceral but not to somatic stimuli. [29] This corresponds well with the situation of our study done during early labor. [1] Third, nonobstetrical preliminary studies have shown that small doses of intrathecal clonidine (from 75 [micro sign]g to 30 - 25 [micro sign]g) significantly increase the duration of postoperative analgesia. [30] [double vertical bar] [double vertical bar]##*** Our results confirm this rationale. The mean duration of additional analgesia obtained in the current study with the addition of 30 [micro sign]g intrathecal clonidine averages 30 min and therefore is nearly comparable to the [almost equal to] 40 min prolongation afforded by the addition of 100 - 200 [micro sign]g intrathecal clonidine to 2 - 7 [micro sign]g intrathecal sufentanil. [12] [double vertical bar]# It is also comparable to the 35-min prolongation obtained with the addition of 2.5 mg intrathecal bupivacaine to intrathecal sufentanil. [6] 
Hemodynamic Effects
The potential for hypotension after neuraxial administration of clonidine is well established. [12] However, we did not expect the important increase in both the incidence and intensity of hypotension that we observed with the addition of a dose as low as 30 [micro sign]g intrathecal clonidine. The dose response for epidural or intrathecal clonidine is generally considered to be U shaped. [12,31,32] Filos et al. [33] found that 150 [micro sign]g intrathecal clonidine decreased blood pressure by 21% when administered 45 min after cesarean section delivery, whereas larger doses (300 or 450 [micro sign]g) were not associated with this side-effect. When smaller doses (75 [micro sign]g to 30 - 25 [micro sign]g) of clonidine were associated with a local anesthetic to perform spinal anesthesia for nonobstetrical surgery, no additional hypotensive effect was first observed.##,*** As recently noted, [12] it also appeared promising that no significant hemodynamic change had occurred during anal surgery when 60 [micro sign]g clonidine had been added to only 2.5 mg intrathecal bupivacaine.[double vertical bar] [double vertical bar] Finally, because 200 [micro sign]g intrathecal clonidine alone[double vertical bar] or 100 [micro sign]g intrathecal clonidine in combination with intrathecal sufentanil# induced significant hypotensive effects in parturients, it was tempting to speculate that lower doses of intrathecal clonidine should be investigated.
Nonetheless, our results clearly show that even 30 [micro sign]g intrathecal clonidine added to intrathecal sufentanil still produces similar untoward hypotensive effects. This is not related to an increased cephalad spread (Figure 3A vs. Figure 3B), but rather might have been promoted by the combined effects of the opioid with clonidine, as described for epidural procedures. [34] Alternatively, parturients might be particularly sensitive to intrathecal clonidine. However, significant hypotensive effects from low clonidine doses were also observed recently in nonpregnant patients. [30] These results do not necessarily conflict with those of Gautier et al., [18] who reported no significant exacerbation of maternal hypotension when 15 or 30 [micro sign]g clonidine was combined with various doses of intrathecal sufentanil during labor. A trend was noted in each small group that had received clonidine, and this might have become significant with more patients or fewer groups. On the other hand, the 5-mg bupivacaine test dose we administered epidurally soon after spinal analgesia may have interacted with intrathecal clonidine to enhance its hypotensive effect. Nevertheless, it is reassuring to note that it did not increase the incidence of abnormal fetal heart rate patterns or alter Apgar scores or umbilical arterial pH. This confirms that maternal hypotension has no adverse consequence on fetal or neonatal well-being provided that it is rapidly reversed by intravenous doses of ephedrine.
A paradoxical higher maternal heart rate was observed in parturients who received clonidine in addition to sufentanil. This difference is clinically unimportant but statistically significant and still observed when parturients who received ephedrine are excluded. It might be a reflex tachycardia related to the decrease in SBP. However, a study conducted in nonpregnant patients did not demonstrate any effect of low doses of clonidine (75 [micro sign]g to 50 - 30 [micro sign]g) on heart rate.## Thus this result might be specific to pregnant women and interesting given further physiopharmacologic investigations.
In conclusion, this double-blinded, randomized study shows that the addition of 30 [micro sign]g intrathecal clonidine to 5 [micro sign]g intrathecal sufentanil extends the duration of labor analgesia without producing any motor blockade. However, the incidence of hypotension and the ephedrine requirements were markedly increased. There were no obvious adverse effects of this hypotension in this group of healthy parturients, and there was a minor benefit.
[double vertical bar] Chiari A, Taslimi R, Sliutz G, Klimscha W: Subarachnoid labour analgesia with sufentanil and clonidine [Abstract]. Br J Anaesth 1995; 74:352A
# Chiari A, Lorber C, Taslimi R, Kainz C, Klimscha W: Analgesia during first stage of labor with intrathecal sufentanil and clonidine [Abstract]. Anesthesiology 1995; 83:A947
** Arkoosh VA, Torjman MC, Montgomery OC, Leighton BL, Norris MC: Does intrathecal sufentanil depress the ventilatory response to CO2in the parturient? [Abstract]. Anesthesiology 1994; 81:A1147
[dagger, dagger] Courant N, Raiga J, Monteillard C, Curt I, Schoeffler P: Intrathecal sufentanil for labor analgesia: A dose-response study [Abstract]. Anesthesiology 1994; 81:A1142
[double dagger] [double dagger] Abouleish A, Camann W, Holden D, Emami A, Eisenach J, Yun E, Datta S: Antinociceptive interaction between intrathecal sufentanil and epidural bupivacaine: Additivity or synergism? [Abstract]. Anesthesiology 1994; 81:A1144
[section] [section] Gaiser R, Adams H, Cheek TG, Gutsche BB: Comparison of three different doses of intrathecal fentanyl and sufentanil for labor analgesia [Abstract]. Reg Anesth 1995; 20(suppl 2S):75
[double vertical bar] [double vertical bar] Pendeville P, Van Boven M, Ledent M, De Kock M: subarachnoid clonidine and minimal dose of HB bupivacaine for saddle block [Abstract]. Reg Anesth 1992; 17(suppl 3S):30
##Celleno D, Capogna G, Emanuelli M, Constantino P, Sebastiani M, Di Sabato A: Spinal bupivacaine and clonidine: hemodynamic and analgesic effects of different doses [Abstract]. Int Monit Reg Anesth 1995; 7:67
***Vidal A, Ayuso M, Ruiz M, Frutos S, Sanz M, Lasheras MA: Intrathecal clonidine vs fentanyl in spinal anesthesia: Comparative side-effects and postoperative analgesia [Abstract]. Int Monit Reg Anesth 1995; 7:106
REFERENCES
Honet JE, Arkoosh VA, Norris MC, Huffnagle HJ, Silverman NS, Leighton BL: Comparison among fentanyl, meperidine, and sufentanil for labor analgesia. Anesth Analg 1992; 75:734-9
Grieco WM, Norris MC, Leighton BL, Arkoosh VA, Huffnagle HJ, Honet JE, Costello D: Intrathecal sufentanil labor analgesia: The effects of adding morphine or epinephrine. Anesth Analg 1993; 77:1149-54
Cohen SE, Cherry CM, Holbrook RH, El-Sayed YY, Gibson RN, Jaffe RA: Intrathecal sufentanil for labor analgesia-sensory changes, side-effects, and fetal heart rate changes. Anesth Analg 1993; 77:1155-60
Camann WR, Minster BH, Denney RA, Datta S: Intrathecal sufentanil for labor analgesia. Effect of added epinephrine. Anesthesiology 1993; 78:870-4
D'Angelo R, Anderson MT, Philip J, Eisenach JC: Intrathecal sufentanil compared to epidural bupivacaine for labor analgesia. Anesthesiology 1994; 80:1209-15
Campbell DC, Camann WR, Datta S: The addition of bupivacaine to intrathecal sufentanil for labor analgesia. Anesth Analg 1995; 81:305-9
Collis RE, Baxandall ML, Srikantharajah ID, Edge G, Kadim MY, Morgan BM: Combined spinal epidural (CSE) analgesia: Technique, management, and outcome of 300 mothers. Int J Obstet Anesth 1994; 3:75-81
Abouleish A, Abouleish E, Camann W: Combined spinal-epidural analgesia in advanced labour. Can J Anaesth 1994; 41:575-8
Collis RE, Davies DWL, Aveling W: Randomised comparison of combined spinal-epidural and standard epidural analgesia in labour. Lancet 1995; 345:1413-6
D'Angelo R, Eisenach JC: Severe maternal hypotension and fetal bradycardia after a combined spinal epidural anesthetic. Anesthesiology 1997; 87:166-8
Campbell DC, Banner R, Crone L-A, Gore-Hickman W, Yip RW: Addition of epinephrine to intrathecal bupivacaine and sufentanil for ambulatory labor analgesia. Anesthesiology 1997; 86:525-31
Eisenach JC, De Kock Klimscha W: [Greek small letter alpha] (2-adrenergic) agonists for regional anesthesia. A clinical review of clonidine (1984-1995). Anesthesiology 1996; 85:655-74
Mercier FJ, Boulay G, Ben Ayed M, Benhamou D: Analgesie rachidienne et peridurale combinee pour le travail. Prolongation par l'adjonction d'une minidose de clonidine au sufentanil. Etude preliminaire. Ann Fr Anesth Reanim 1996; 15:263-5
Mercier FJ, Bouaziz H, Benhamou D: Transition from intrathecal analgesia to epidural anesthesia for emergency cesarean section using a combined spinal epidural technique [Letter]. Anesth Analg 1996; 83:434
Phillips G: Continuous infusion epidural analgesia in labor: The effect of adding sufentanil to 0.125% bupivacaine. Anesth Analg 1988; 67:462-5
Mantha S, Thisted R, Foss J, Ellis JE, Roizen MF: A proposal to use confidence intervals for visual analog scale data for pain measurement to determine clinical significance. Anesth Analg 1993; 77:1041-7
Dexter F, Chesnut DH: Analysis of statistical tests to compare visual analog scale measurements among groups. Anesthesiology 1995; 82:896-902
Gautier P, De Kcok M, Fanard L, Hody JL: Low doses intrathecal clonidine combined with sufentanil for labor analgesia [Abstract]. Anesthesiology 1997; 87:A899
Norris MC, Ryan C, Fogel ST, Holtmann B: Intrathecal sufentanil increases end-tidal CO2in laboring women [Abstract]. Anesthesiology 1997; 87:A885
Hamilton CL, Cohen SE: High sensory block after intrathecal sufentanil for labor analgesia. Anesthesiology 1995; 83:1118-21
Hays RL, Palmer CM: Respiratory depression after intrathecal sufentanil during labor. Anesthesiology 1994; 81:511-2
Greenhalgh CA: Respiratory arrest in a parturient following intrathecal injection of sufentanil and bupivacaine. Anaesthesia 1996; 51:173-5
Ferouz F, Norris MC, Leighton BL: Risk of respiratory arrest after intrathecal sufentanil. Anesth Analg 1997; 85:1088-90
Gautier PE, Debry F, Fanard L, Van Steenberge A, Hody J-L: Ambulatory combined spinal-epidural analgesia for labor. Influence of epinephrine on bupivacaine-sufentanil combination. Reg Anesth 1997; 22:143-9
Norris MC, Grieco WM, Borkowski M, Leighton BL, Arkoosh VA, Huffnagle HJ, Huffnagle S: Complications of labor analgesia: Epidural versus combined spinal epidural techniques. Anesth Analg 1994; 79:529-37
Herman NL, Calicott R, Van Decar TK, Conlin G, Tilton J: Determination of the dose-response relationship for intrathecal sufentanil in laboring patients. Anesth Analg 1997; 84:1256-61
Ossipov MH, Suarez LJ, Spaulding TC: Antinociceptive interactions between alpha2-adrenergicand opiate agonist at the spinal level in rodents. Anesth Analg 1989; 68:194-200
Meert TF, De Kock M: Interactions between the lipophilic opioid sufentanil and clonidine in rats after spinal application. Acta Anaesthesiol Scand 1995; 39:527-34
Iwasaki H, Collins JG, Saito Y, Uchida H, Kerman-Hinds A: Low-dose clonidine enhances pregnancy-induced analgesia to visceral but not to somatic stimuli in rats. Anesth Analg 1991; 72:325-9
Kindler C, Gurzeler J, Aeschbach A, Paganoni R, Schneider M: Dose-response study of intrathecal clonidine [Abstract]. Anesthesiology 1997; 87:A811
Eisenach JC, Dewan DM. Intrathecal clonidine in obstetrics: Sheep studies. Anesthesiology 1990; 72:663-8
Eisenach JC, Lysak SZ, Viscomi CM: Epidural clonidine analgesia following surgery: Phase I. Anesthesiology 1989; 71:640-6
Filos KS, Goudas LC, Patroni O, Polyzou V: Hemodynamic and analgesic profile after intrathecal clonidine in humans. A dose-response study. Anesthesiology 1994; 81:591-601
Eisenach JC, D'Angelo R, Taylor C, Hood DD: An isobolographic study of epidural clonidine and fentanyl after cesarean section. Anesth Analg 1994; 79:285-90
Figure 1. The duration of spinal analgesia, as the percentage of parturients not requesting additional analgesia, after intrathecal injection of 5 [micro sign]g sufentanil plus 30 [micro sign]g clonidine (dotted line) or 5 [micro sign]g sufentanil alone (solid line). The two groups differ according to Kaplan-Meier survival analysis followed by the log-rank test.
Figure 1. The duration of spinal analgesia, as the percentage of parturients not requesting additional analgesia, after intrathecal injection of 5 [micro sign]g sufentanil plus 30 [micro sign]g clonidine (dotted line) or 5 [micro sign]g sufentanil alone (solid line). The two groups differ according to Kaplan-Meier survival analysis followed by the log-rank test.
Figure 1. The duration of spinal analgesia, as the percentage of parturients not requesting additional analgesia, after intrathecal injection of 5 [micro sign]g sufentanil plus 30 [micro sign]g clonidine (dotted line) or 5 [micro sign]g sufentanil alone (solid line). The two groups differ according to Kaplan-Meier survival analysis followed by the log-rank test.
×
Figure 2. The onset of spinal analgesia assessed by visual analog pain score (VAPS), after intrathecal injection of 5 [micro sign]g sufentanil plus 30 [micro sign]g clonidine (SUF-CLO) or 5 [micro sign]g sufentanil alone (SUF). Each point represents the mean +/- 95% confidence interval. All VAPSs beyond baseline differ from their respective baseline values, but there was no significant difference between the two groups.
Figure 2. The onset of spinal analgesia assessed by visual analog pain score (VAPS), after intrathecal injection of 5 [micro sign]g sufentanil plus 30 [micro sign]g clonidine (SUF-CLO) or 5 [micro sign]g sufentanil alone (SUF). Each point represents the mean +/- 95% confidence interval. All VAPSs beyond baseline differ from their respective baseline values, but there was no significant difference between the two groups.
Figure 2. The onset of spinal analgesia assessed by visual analog pain score (VAPS), after intrathecal injection of 5 [micro sign]g sufentanil plus 30 [micro sign]g clonidine (SUF-CLO) or 5 [micro sign]g sufentanil alone (SUF). Each point represents the mean +/- 95% confidence interval. All VAPSs beyond baseline differ from their respective baseline values, but there was no significant difference between the two groups.
×
Figure 3. Box plots representing the spread of the upper level of sensory changes to cold in parturients receiving intrathecal injections of (A) 5 [micro sign]g sufentanil plus 30 [micro sign]g clonidine (SUF-CLO) or (B) 5 [micro sign]g sufentanil alone (SUF). The horizontal line within the box represents the median, whereas the box itself represents the interquartile range, with outliers represented by open circles. There was no significant difference between groups, and cephalad sensory changes never exceeded T2.
Figure 3. Box plots representing the spread of the upper level of sensory changes to cold in parturients receiving intrathecal injections of (A) 5 [micro sign]g sufentanil plus 30 [micro sign]g clonidine (SUF-CLO) or (B) 5 [micro sign]g sufentanil alone (SUF). The horizontal line within the box represents the median, whereas the box itself represents the interquartile range, with outliers represented by open circles. There was no significant difference between groups, and cephalad sensory changes never exceeded T2.
Figure 3. Box plots representing the spread of the upper level of sensory changes to cold in parturients receiving intrathecal injections of (A) 5 [micro sign]g sufentanil plus 30 [micro sign]g clonidine (SUF-CLO) or (B) 5 [micro sign]g sufentanil alone (SUF). The horizontal line within the box represents the median, whereas the box itself represents the interquartile range, with outliers represented by open circles. There was no significant difference between groups, and cephalad sensory changes never exceeded T2.
×
Figure 4. (A) Systolic blood pressure (SBP) after intrathecal injection of 5 [micro sign]g sufentanil plus 30 [micro sign]g clonidine (SUF-CLO) or 5 [micro sign]g sufentanil alone (SUF). Despite prompt treatment of hypotension with intravenous ephedrine, the SBP remained significantly lower in the SUF-CLO group (P = 0.02). *P < 0.05 with Bonferroni corrections compared with the SUF group. (B) Kaplan-Meier survival analysis representing the time course of intravenous ephedrine administration after intrathecal injection of 5 [micro sign]g sufentanil plus 30 [micro sign]g clonidine (dotted line) or 5 [micro sign]g sufentanil alone (solid line). Administration of ephedrine was still required 65 - 120 min after intrathecal injection on four occasions in the SUF-CLO group, whereas no patient had hypotension beyond 45 min in the SUF group.
Figure 4. (A) Systolic blood pressure (SBP) after intrathecal injection of 5 [micro sign]g sufentanil plus 30 [micro sign]g clonidine (SUF-CLO) or 5 [micro sign]g sufentanil alone (SUF). Despite prompt treatment of hypotension with intravenous ephedrine, the SBP remained significantly lower in the SUF-CLO group (P = 0.02). *P < 0.05 with Bonferroni corrections compared with the SUF group. (B) Kaplan-Meier survival analysis representing the time course of intravenous ephedrine administration after intrathecal injection of 5 [micro sign]g sufentanil plus 30 [micro sign]g clonidine (dotted line) or 5 [micro sign]g sufentanil alone (solid line). Administration of ephedrine was still required 65 - 120 min after intrathecal injection on four occasions in the SUF-CLO group, whereas no patient had hypotension beyond 45 min in the SUF group.
Figure 4. (A) Systolic blood pressure (SBP) after intrathecal injection of 5 [micro sign]g sufentanil plus 30 [micro sign]g clonidine (SUF-CLO) or 5 [micro sign]g sufentanil alone (SUF). Despite prompt treatment of hypotension with intravenous ephedrine, the SBP remained significantly lower in the SUF-CLO group (P = 0.02). *P < 0.05 with Bonferroni corrections compared with the SUF group. (B) Kaplan-Meier survival analysis representing the time course of intravenous ephedrine administration after intrathecal injection of 5 [micro sign]g sufentanil plus 30 [micro sign]g clonidine (dotted line) or 5 [micro sign]g sufentanil alone (solid line). Administration of ephedrine was still required 65 - 120 min after intrathecal injection on four occasions in the SUF-CLO group, whereas no patient had hypotension beyond 45 min in the SUF group.
×
Figure 5. The maternal heart rate (MHR) after intrathecal injection 5 [micro sign]g sufentanil plus 30 [micro sign]g clonidine (SUF-CLO) or 5 [micro sign]g sufentanil alone (SUF). The MHR was significantly higher in the SUF-CLO group (P < 0.0001). *P < 0.05 with Bonferroni corrections compared with the SUF group.
Figure 5. The maternal heart rate (MHR) after intrathecal injection 5 [micro sign]g sufentanil plus 30 [micro sign]g clonidine (SUF-CLO) or 5 [micro sign]g sufentanil alone (SUF). The MHR was significantly higher in the SUF-CLO group (P < 0.0001). *P < 0.05 with Bonferroni corrections compared with the SUF group.
Figure 5. The maternal heart rate (MHR) after intrathecal injection 5 [micro sign]g sufentanil plus 30 [micro sign]g clonidine (SUF-CLO) or 5 [micro sign]g sufentanil alone (SUF). The MHR was significantly higher in the SUF-CLO group (P < 0.0001). *P < 0.05 with Bonferroni corrections compared with the SUF group.
×
Table 1. Demographic and Obstetric Data
Image not available
Table 1. Demographic and Obstetric Data
×
Table 2. Labor Analgesia Data and Maternal Side Effects during Intrathecal Analgesia
Image not available
Table 2. Labor Analgesia Data and Maternal Side Effects during Intrathecal Analgesia
×
Table 3. Fetal Heart Rate Patterns during the First 30 min after Intrathecal Injection and Neonatal Outcome Data
Image not available
Table 3. Fetal Heart Rate Patterns during the First 30 min after Intrathecal Injection and Neonatal Outcome Data
×